Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)



Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $795.32million.

After announcing two years ago that it would stop working on depression drug Serdaxin, Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) has since shifted its focus to the discovery and development of new drugs to treat cancer. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s stock on Mar 06, 2014 reported a decrease of -1.37% to the closing price of $1.44. Its fifty two weeks range is $0.28 -$1.85. The total market capitalization recorded $67.27billion. The overall volume in the last trading session was 7.89million shares. In its share capital, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has 130.47million outstanding shares.

In a recent SA article, Michael Webb claimed that the subconscious of FDA AdCom panel members reviewing MannKind Corporation (NASDAQ:MNKD)’s Afrezza could lead to it being rejected. MannKind Corporation (NASDAQ:MNKD) stock performance was -3.06% in last session and finished the day at $5.71. Traded volume was 8.10million shares in the last session and the average volume of the stock remained 7.13million shares. The beta of the stock remained 1.77. MannKind Corporation (NASDAQ:MNKD) insider ownership is 0.60%.

Peregrine Pharmaceuticals (NASDAQ:PPHM) was able to achieve a strong gain where the share prices soared more than 50 percent on Wednesday. On Wednesday, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) dropped -7.46% to close the day at $2.61. Company return on investment (ROI) is -126.10% and its monthly performance is recorded as 49.14%. Peregrine Pharmaceuticals (NASDAQ:PPHM) quarterly revenue growth is 94.78%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone